Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Tai-Xing Cui
Fluvastatin Enhances the Inhibitory Effects of a Selective AT1 Receptor Blocker, Valsartan, on Atherosclerosis
Hypertension
Internal Medicine
Related publications
Effects of Valsartan, an Angiotensin II Receptor Blocker, on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction Who Receive an Angiotensin-Converting Enzyme Inhibitor
Circulation Journal
Medicine
Cardiovascular Medicine
Cardiology
The Non-Biphenyl-Tetrazole AT1 Receptor Blocker Eprosartan Is a Unique and Robust Inverse Agonist of the Active State of AT1 Receptor
British Journal of Pharmacology
Pharmacology
Effect of the Angiotensin Receptor Blocker Valsartan on Morbidity and Mortality in Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT)
Circulation
Cardiovascular Medicine
Physiology
Cardiology
Angiotensin II Type 1 (AT1) Receptor Deficiency Halts the Progression of Age-Related Atherosclerosis in Hypercholesterolemia: Molecular Link Between the AT1 Receptor and Hypercholesterolemia
Hypertension Research
Internal Medicine
Cardiovascular Medicine
Physiology
Cardiology
The Impact of Dose of the Angiotensin-Receptor Blocker Valsartan on the Post-Myocardial Infarction Ventricular Remodeling: Study Protocol for a Randomized Controlled Trial
Trials
Medicine
Pharmacology
Effects of an Inorganic Ca2+-Channel Blocker (Lanthanum) on Experimental Atherosclerosis in Rabbits
The Journal of Japan Atherosclerosis Society
Combined Inhibitory Effects of Celecoxib and Fluvastatin on the Growth of Human Hepatocellular Carcinoma Xenografts in Nude Mice
Journal of International Medical Research
Biochemistry
Medicine
Cell Biology
Effects of a Highly Selective Acetylcholine-Activated K+ Channel Blocker on Experimental Atrial Fibrillation
Circulation: Arrhythmia and Electrophysiology
Medicine
Cardiovascular Medicine
Physiology
Cardiology
Internalization of Constitutively Active N111G Mutant of AT1 Receptor Induced by Angiotensin II–Receptor Antagonists Candesartan, Losartan, and Telmisartan: Comparison With Valsartan
Journal of Pharmacological Sciences
Molecular Medicine
Pharmacology
